8-K Announcements
6Material company update
Mar 31, 2026·SEC
Material company update
Mar 3, 2026·SEC
Material company update
Mar 3, 2026·SEC
Tharimmune, Inc.(THAR)Earnings, Financials & Key Ratios
THAR•NASDAQ
$3.54
Price updated Jun 20, 2026
AboutTharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.Show more
- Revenue$0
- EBITDA-$42M-232.4%
- Net Income-$36M-194.5%
- EPS (Diluted)-1.12+88.1%
- ROE-17.99%+92.3%
THAR Price & Volume
Tharimmune, Inc. (THAR) stock price & volume — 10-year historical chart
Loading chart...
Goodwill Accumulation Masks Persistent Operational Cash Burn
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical trial dependency
"Tharimmune remains a high-risk, pre-revenue biotechnology entity characterized by significant clinical trial dependency and a volatile expense profile. While the company has attempted to scale its operations, the recent surge in SG&A to $36.6 million in 2026Q1 and heavy reliance on stock-based compensation suggest potential long-term dilution risks for shareholders. Investors should monitor the sustainability of the current $41.5 million cash position against the backdrop of a $54.8 million free cash flow deficit observed in the most recent quarter."
Verdict Logic
the company's reliance on $32.3 million in stock-based compensation to manage its $47.3 million net loss in 2026Q1, combined with a $54.8 million free cash flow deficit, suggests significant ongoing capital requirements that may necessitate further dilutive financing.
THAR Growth Metrics
Tharimmune, Inc. (THAR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-546.61%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM74.36%
Return on Capital
10 Years-304.6%
5 Years-304.6%
3 Years-124.95%
Last Year-7.78%
THAR Recent Earnings
Tharimmune, Inc. (THAR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (22%)
Q2 2026Latest
Mar 31, 2026Metric
Actual
Est
EPS
$0.79-88.1%
$0.42
Rev
—
—
Q2 2026
Mar 24, 2026Metric
Actual
Est
EPS
$2.02-381.0%
$0.42
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.34+20.9%
$0.43
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.64-10.3%
$0.58
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 31, 2026 | $0.79vs $0.42-88.1% | — |
| Q2 2026 | Mar 24, 2026 | $2.02vs $0.42-381.0% | — |
| Q4 2025 | Nov 12, 2025 | $0.34vs $0.43+20.9% | — |
| Q3 2025 | Aug 14, 2025 | $0.64vs $0.58-10.3% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Tharimmune, Inc. (THAR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.54 | $139.94M | -0.38 | — | — | -17.99% | — | |
| $74.96 | $8.89B | 29.28 | 37.55% | 23.13% | 126.27% | — | |
| $10.02 | $524.58M | -2.21 | -92.84% | -260.92% | -49.88% | — | |
| $1.83 | $110.39M | -3.27 | — | — | -0% | — | |
| $35.26 | $2.35B | -9.04 | -78.63% | -34596.22% | -50.72% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — |
Compare THAR vs Peers
Tharimmune, Inc. (THAR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
THAR SEC Filings & Documents
Tharimmune, Inc. (THAR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when THAR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
THAR Frequently Asked Questions
Tharimmune, Inc. (THAR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is THAR profitable?
Tharimmune, Inc. (THAR) reported a net loss of $80.7M for fiscal year 2025.
Dividend & Returns
What is THAR's return on equity?
Tharimmune, Inc. (THAR) has a return on equity (ROE) of -18.0%. Negative ROE indicates the company is unprofitable.
What is Tharimmune, Inc.'s free cash flow?
Tharimmune, Inc. (THAR) had negative free cash flow of $21.1M in fiscal year 2025, likely due to heavy capital investments.